A Facebook Share widget found on Novartis’ Tasigna (nilotinib) website provoked a DDMAC untitled letter, the fourth DDMAC communiqué Novartis has received this year. In a rare bit of footnoted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback